Home Tumor Foundation Models Surge: How to Seize Industry Opportunities? [AI for Life Special Webinar Series #9]

Tumor Foundation Models Surge: How to Seize Industry Opportunities? [AI for Life Special Webinar Series #9]

Oct 15, 2025 08:00 CST Updated 08:00

To accelerate the adoption of large language model (LLM) technologies across various healthcare scenarios, VCBeat is launching a special live-streaming series titled “AI for Life.” Conducted as online webinars, each session will feature 3–4 leading enterprises and industry experts in China’s LLM sector. The discussions will focus on specific LLM application scenarios to address implementation challenges, connect ecosystem resources, and foster greater ecological collaboration and supply-demand matchmaking.


Since the beginning of this year, large AI models for cancer (oncology) in China have been advancing vigorously and have achieved phased milestones, spanning cancers such as pancreatic, breast, prostate, and liver cancer, and covering the entire patient journey from consultation and diagnosis to disease-specific full-course management. Meanwhile, challenges related to data governance, clinical adaptation, and generalization capabilities of these oncology large models remain prominent, underscoring an urgent need for effective solutions.


In this context,On October 15 at 4:00 PM, the ninth session of VCBeat’s “AI for Life” special live-streaming series featured four industry representatives: Wang Jiejun, Chief Physician at the First Affiliated Hospital of Bengbu Medical University; Gao Liang, Attending Physician at the Second Affiliated Hospital of Chongqing Medical University; Jiao Zengtao, Senior Algorithm Architect at Yidu Tech; and Zhao Jun, Senior Researcher at JD Health’s Exploration Institute., deconstructing the current development status, challenges, and future of domestic large language models for cancer (oncology) from dimensions such as “selection of disease types/implementation pathways,” “data acquisition and governance,” and “enhancement of generalization capability and clinical adaptability.”


肿瘤大模型宣传海报.jpg